ClinicalTrials.gg
Enrolling by invitationNCT05604976SPEEDYPCIUpdated Nov 13, 2023

Single Catheter Primary Percutaneous Coronary Intervention Method in Patients With ST Elevation Myocardial Infarction

An interventional study of Percutaneous coronary intervention in ST Elevation Myocardial Infarction, sponsored by Tokai University. Enrolling by invitation at 1 site in Japan. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Tokai University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in ST Elevation Myocardial Infarction with a site in Japan — 1 open to participants now, 2 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Japan.

Started
2022
the only one that year
No phase
5 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
2 of 10
Tokai University

Among the 10 studies in ST Elevation Myocardial Infarction with a site in Japan, this one is the only one that started in 2022, is one of 5 with no phase, and was the 8th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

1 of the 10 studies in ST Elevation Myocardial Infarction with a site in Japan is open now.

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in ST Elevation Myocardial Infarction with a site in Japan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test reducing procedure time of percutaneous coronary intervention (PCI) in ST elevation myocardial infarction by single catheter PCI (SC-PCI) method. The main question it aims to answer is:

  • [question 1] SC-PCI method is skipping catheter exchange with use of a right and left dual purpose universal guiding catheter Ikari Left curve. Does SC-PCI method reduce PCI procedure time? Participants will be randomly assigned to SC-PCI method or conventional method and emergency PCI is performed.

Researchers will compare time from sheath insertion to first device activation between the SC-PCI method and the conventional method.

Read the detailed description

\<\<Background>>

Acute ST-segment elevation myocardial infarction is a disease of high acute-phase mortality rate, but the life can be saved by implementing emergency percutaneous coronary intervention (PCI). Its efficacy is higher than that of thrombolytic therapy. Moreover, shortening of total ischemia time reduces the mortality rate and can promote recovery of cardiac function. The total ischemia time can be classified into the time from onset to arrival at hospital and the time from arrival at hospital to recanalization of coronary artery (Door-to-balloon time), and shortening of time in all steps is recommended. Various methods, including the part of transportation to hospital and from arrival at hospital to treatment room, are proposed, but there is no effective method for shortening of procedure time for PCI.

Since the right and left dual-purpose universal guiding catheter can be inserted into both the left and right coronary arteries, the time for replacement of catheter can be shortened. Since IKARI Curve catheter is considered to be the most excellent catheter as the universal guiding catheter, it is considered useful for shortening of reperfusion time in myocardial infarction.

\<\<Objectives.>>

There are a lot of reports that decreased mortality and improvement of cardiac function are observed by shortening of the time from onset of acute myocardial infarction to recanalization. However, shortening of catheterization time, a part of the time, has not been examined. In 60 patients in a single-center retrospective study performed in Tokai University, the time from arterial puncture to reperfusion was shortened, and the time from arrival at hospital to reperfusion was also shortened. In 1275 patients in a multi-center retrospective study, moreover, the time from arterial puncture to reperfusion was significantly shortened by 4 minutes, and a significant decrease was also observed in the time from arrival at hospital to reperfusion. The Door-to-balloon time at this time was 68±46 minutes in the SC-PCI group and 76±51 minutes by the conventional method. Moreover, the time from insertion of sheath to balloon was 19±14 minutes in the SC-PCI group and 23±14 minutes by the conventional method. In addition, shortening of fluoroscopy time was also observed.

Based on this result, the information shall be collected from prospective multi-center randomized study and analyzed to verify that the right and left dual-purpose guiding catheter is useful for shortening of reperfusion time in myocardial infarction.

\<\<Methods.>>

Multi-center cooperative prospective interventional study, 2-group comparative study, and randomization \<Conventional method> If the patients are allocated to this group, the procedure shall be started with an angiographic catheter.

An angiographic catheter is a catheter classified into a special treatment material, "Angiographic Catheter (General Model) Request Code 738180000," and approved for insurance coverage. The catheters adopted by each institution shall be used.

Coronary angiography shall be performed using an angiographic catheter, and PCI shall be performed by replacing to a guiding catheter. There are methods in which a catheter for angiography on right and left sides is performed, a dual-purpose contrast catheter is used, and one contrast catheter and guiding catheter are used, but any method is acceptable if the procedure is started from an angiographic catheter.

\<SC-PCI method> When allocated to this group, the procedure shall be started with a guiding catheter of Ikari L Curve. As the Ikari L Curves approved for insurance coverage in Japan, 52 types exist by catalogue according to the difference in diameter and form, of 6 shafts of 5 companies (attached documents). Any of them shall be used. Thereafter, the right and left coronary angiography shall be performed with one right and left dual-purpose guiding catheter, and then PCI shall be performed.

Even if allocated to any group, Synergy stent shall be used when a stent is placed in coronary artery dilation.

A prospective randomization study shall be performed to reduce the bias. For the Sheath-to-First device activation time, a primary endpoint, a test of superiority shall be performed. For the Door-to-balloon time, a secondary endpoint, a test of non-inferiority shall be performed, and if the non-inferiority is demonstrated, a test of superiority shall also be performed.

The primary endpoint shall be analyzed by Intention-to-treat. The operators who can participate in this study shall take charge of any group, and who are the PCI operators who have used the Ikari L Curve guiding catheter on the right coronary artery in at least 5 patients and left coronary artery in at least 5 patients.

\<\<Number of Target Patients and Rationales for Setting>>

\<Number of target patients> 400 patients in total (200 patients for SC-PCI method, 200 patients for conventional method) \<Rationale for setting> In a multicenter retrospective study, the time from insertion of sheath to balloon (S2B) was 19±14 minutes in the SC-PCI group and 23±14 minutes for the conventional method. When testing at the level of significance of 0.05 and the power of 0.8 based on this value, the number of patients will become 388. Considering 3% dropout cases, registration of a total of 400 patients is planned.

A secondary endpoint, the D2B time was 68±46 minutes in the SC-PCI group and 76±51 minutes for the conventional method as a result of retrospective study. When testing at the level of significance of 0.05 and the power of 0.8 based on this value, the number of patients will become 1160. Therefore, the power is insufficient to show significance in the analysis of D2B time, and a non-inferiority test shall be performed. The margin of noninferiority is set at 1.3. If the D2B time by the conventional method is 76 minutes, the 1.3 times longer time is 98.8 minutes, and the difference is 22.8 minutes. In the treatment of myocardial infarction, the difference of 23 minutes or more is considered to be inferior from the standpoint of expert, and therefore it was set. Non-inferiority test shall be performed based on the 95% confidence interval (test of two-sided 5% or one-sided 2.5%) of the difference from mean value. If non-inferiority is shown, the test of superiority shall also be performed.

03

Conditions studied

  • ST Elevation Myocardial Infarction

Keywords

  • Primary percutaneous coronary intervention
  • Door-to-balloon time
  • guiding catheter
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of 21 years or older
  2. Acute ST-segment elevation myocardial infarction
  3. Patients indicated for Primary PCI within 12 hours after onset

Exclusion criteria

Exclusion Criteria:

  1. Patients with shock requiring insertion of Impella, ECMO or IABP before PCI
  2. Patients requiring cardiopulmonary resuscitation due to cardiac arrest
  3. Patients requiring temporary pacemaker due to bradycardia
  4. Patients undergoing dialysis
  5. Patients judged by the attending physician to be inappropriate for registration
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    SC-PCI

    Primary PCI is initiated with a universal guiding catheter (Ikari left). The guiding catheter is used to contrast the left and right coronary arteries and PCI is started directly. This method does not require a catheter exchange. It is Single Catheter PCI (SC-PCI) method.

    Device: Percutaneous coronary intervention

  • Active comparator
    Conventional

    Primary PCI is initiated with a diagnostic catheter. The catheter is used to contrast one of the coronary arteries. Then, the catheter is replaced with a contralateral side diagnostic catheter. Then, the catheter is replaced with a guiding catheter and PCI is started.

    Device: Percutaneous coronary intervention

Interventions

  • DevicePercutaneous coronary intervention

    Primary PCI for ST elevation myocardial infarction initiating with a universal guiding catheter or an angiographic catheter

06

What researchers measure

Primary outcomes

  1. Sheath-to-first device activation time

    Time from insertion of sheath to reperfusion treatment apparatus (First device activation)

    Time frame: the end of PCI

Secondary outcomes

  1. Door-to-balloon time

    Time from arrival at hospital to reperfusion treatment apparatus (First device activation)

    Time frame: the end of PCI

  2. Total ischemia time

    Time from the onset of myocardial infarction to achievement of TIMI 3 reperfusion

    Time frame: the end of PCI

  3. Fluoroscopy time and fluoroscopy dose

    Radiation dose assessed as fluoroscopy time and dose

    Time frame: the end of PCI

  4. Amount of contrast medium

    Dose of contrast medium used during PCI procedure

    Time frame: the end of PCI

  5. Number of catheters used

    Total number of catheters used during the PCI procedure

    Time frame: the end of PCI

  6. Hospital expense

    Total cost required for the total hospital stay

    Time frame: 30 days

  7. All-cause mortality and cardiovascular mortality at 30 days

    All-cause mortality and cardiovascular mortality at 30 days

    Time frame: At 30 days from the onset of STEMI

  8. Hemorrhagic complication rate at 30 days

    BARC 3 or 5 hemorrhagic complications

    Time frame: At 30 days from the onset of STEMI

  9. All-cause mortality and cardiovascular mortality at 1 year

    All-cause mortality and cardiovascular mortality at 1 year

    Time frame: 1 year after the randomization

  10. Success rate of SC-PCI method

    Success of SC-PCI method is defined as diagnostic angiography and PCI is performed using a single universal guiding catheter, Ikari left.

    Time frame: the end of PCI

07

Study locations

1 site
08

References and documents

Publications

  • Lee KH, Torii S, Oguri M, Miyaji T, Kiyooka T, Ono Y, Asada K, Adachi T, Takahashi A, Ikari Y. Reduction of door-to-balloon time in patients with ST-elevation myocardial infarction by single-catheter primary percutaneous coronary intervention method. Catheter Cardiovasc Interv. 2022 Feb;99(2):314-321. doi: 10.1002/ccd.29797. Epub 2021 May 31. PubMed 34057275 ↗
  • Torii S, Fujii T, Murakami T, Nakazawa G, Ijichi T, Nakano M, Ohno Y, Shinozaki N, Yoshimachi F, Ikari Y. Impact of a single universal guiding catheter on door-to-balloon time in primary transradial coronary intervention for ST segment elevation myocardial infarction. Cardiovasc Interv Ther. 2017 Apr;32(2):114-119. doi: 10.1007/s12928-016-0395-z. Epub 2016 Apr 28. PubMed 27125428 ↗
  • Youssef AA, Hsieh YK, Cheng CI, Wu CJ. A single transradial guiding catheter for right and left coronary angiography and intervention. EuroIntervention. 2008 Jan;3(4):475-81. doi: 10.4244/eijv3i4a85. PubMed 19736091 ↗
  • Ikari Y, Masuda N, Matsukage T, Ogata N, Nakazawa G, Tanabe T, Morino Y. Backup force of guiding catheters for the right coronary artery in transfemoral and transradial interventions. J Invasive Cardiol. 2009 Nov;21(11):570-4. PubMed 19901410 ↗
  • Ikari Y, Nagaoka M, Kim JY, Morino Y, Tanabe T. The physics of guiding catheters for the left coronary artery in transfemoral and transradial interventions. J Invasive Cardiol. 2005 Dec;17(12):636-41. PubMed 16327043 ↗
  • Ikari Y, Nakajima H, Iijima R, Aoki J, Tanabe K, Nakayama T, Miyazawa A, Hatori M, Kyouno H, Tanimoto S, Amiya E, Nakazawa G, Onuma Y, Hara K. Initial characterization of Ikari Guide catheter for transradial coronary intervention. J Invasive Cardiol. 2004 Feb;16(2):65-8. PubMed 14760193 ↗
  • Ikari Y, Ochiai M, Hangaishi M, Ohno M, Taguchi J, Hara K, Isshiki T, Tamura T, Yamaguchi T. Novel guide catheter for left coronary intervention via a right upper limb approach. Cathet Cardiovasc Diagn. 1998 Jun;44(2):244-7. doi: 10.1002/(sici)1097-0304(199806)44:23.0.co;2-l. PubMed 9637453 ↗

Individual participant data

Plan to share: No — There are no plans to obtain IPD consent from patients.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Dec 2024, 25 months after the start.

Of 135 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 25 months is below that.

Counting every sponsor, half of 145 studies reached it within 40 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2022
First posted
Nov 3, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Dec 20, 2024
CompletionEst.
Dec 20, 2025
Last update
Nov 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05604976
Lead sponsor
Tokai University
Responsible party
Sho Torii (Associate Professor, Department of Cardiology, Tokai University) — Principal investigator
First posted
Nov 3, 2022
Start date
Nov 1, 2022
Primary completion
Dec 20, 2024 (estimated)
Completion
Dec 20, 2025 (estimated)
Last update
Nov 13, 2023

Study contacts

Sho Torii, MD
principal investigator · Tokai University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion